{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:37:13Z","timestamp":1773873433968,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T00:00:00Z","timestamp":1569110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2019.09.074","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T08:02:28Z","timestamp":1569916948000},"page":"4476-4483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report"],"prefix":"10.1016","volume":"38","author":[{"given":"Maria Rosario","family":"Capeding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edison","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arijit","family":"Sil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-9104","authenticated-orcid":false,"given":"Samuel","family":"Teshome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchada","family":"Chinaworapong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue-Kyoung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Soo","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hwa","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Anh","family":"Wartel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.074_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004616","article-title":"The burden of typhoid and paratyphoid in India: systematic review and meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2019.09.074_b0010","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","year":"2019","journal-title":"Lancet Infectious Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.074_b0015","first-page":"531","article-title":"Blood culture confirmed typhoid fever in a provincial hospital in the Philippines","volume":"32","author":"Abucejo","year":"2001","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2019.09.074_b0020","unstructured":"GOVPH. Department of Health. 2018 Typhoid Morbidity Week 52. Available at: <https:\/\/www.doh.gov.ph\/sites\/default\/files\/statistics\/2018_TYPHOID_MW52_1.pdf> (Accessed in April 2019)."},{"key":"10.1016\/j.vaccine.2019.09.074_b0025","unstructured":"Background Paper on Typhoid Vaccines for SAGE Meeting (October 2017) <http:\/\/www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_Typhoid_SAGE_background_paper_Final_v3B.pdf>. accessed 22nd February 2019."},{"key":"10.1016\/j.vaccine.2019.09.074_b0030","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.09.074_b0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/649541","article-title":"Global trends in typhoid and paratyphoid fever","volume":"50","author":"Crump","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.074_b0040","series-title":"Nelson Textbook of Pediatrics","first-page":"948","article-title":"Salmonella","author":"Buttha","year":"2011"},{"key":"10.1016\/j.vaccine.2019.09.074_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"J Global Health"},{"key":"10.1016\/j.vaccine.2019.09.074_b0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenecity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adult, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.074_b0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/INF.0b013e3181e39f8b","article-title":"Incidence of typhoid bacteremia in infants and young children in southern coastal Pakistan","volume":"29","author":"Owais","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.09.074_b0060","first-page":"1263","article-title":"The efficacy of Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001"},{"key":"10.1016\/j.vaccine.2019.09.074_b0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.09.074_b0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/jac\/dkl391","article-title":"Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India","volume":"58","author":"Gaind","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2019.09.074_b0075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)00530-7","article-title":"Gatifloxcain versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial","volume":"16","author":"Arjyal","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.074_b0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3201\/eid1605.091917","article-title":"Fluoroquinolone-resistant typhoid, South Africa","volume":"16","author":"Keddy","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.074_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001921","article-title":"Salmonella Typhi in the Democratic Republic of the Congo: fluoroquinolone decreased susceptibility on the rise","volume":"6","author":"Lunguya","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.09.074_b0090","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/CMR.00002-15","article-title":"Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance and antimicrobial management of invasive Salmonella infections","volume":"28","author":"Crump","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.09.074_b0095","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0140-6736(13)62708-7","article-title":"Typhoid fever","volume":"385","author":"Wain","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.09.074_b0100","unstructured":"Yousafzai MT, Qamar FN, Shakoor S, Saleem K, Kazi M, Garett D, et al. Outbreak investigation of cefriaxone resistant S. Typhi in Hyderabad, Pakistan. 10th International Conference on Typhoid and other Invasive Salmonellosis. April 4\u20136. Kampala, Uganda, 2017."},{"key":"10.1016\/j.vaccine.2019.09.074_b0105","doi-asserted-by":"crossref","unstructured":"Typhoid vaccines: WHO position paper, March 2018 - Recommendations. Vaccine. 2019;37(2):214-216, doi:10.1016\/j.vaccine.2018.04.022.","DOI":"10.1016\/j.vaccine.2018.04.022"},{"key":"10.1016\/j.vaccine.2019.09.074_b0110","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings","volume":"35","author":"Antill\u00f3n","year":"2017","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2019.09.074_b0115","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"issue":"S1","key":"10.1016\/j.vaccine.2019.09.074_b0120","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"CID"},{"key":"10.1016\/j.vaccine.2019.09.074_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biologicals.2018.09.001","article-title":"Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG","volume":"56","author":"Rijpkema","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.09.074_b0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-3083.2003.01292.x","article-title":"Mucosal vaccination against encapsulated respiratory bacteria - New potentials for conjugate vaccines?","volume":"58","author":"Jakobsen","year":"2003","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.09.074_b0135","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.vaccine.2011.12.046","article-title":"Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine","volume":"30","author":"An","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.074_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new VI-CRM 197 conjugate vaccine against typhoid fever: Randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.074_b0145","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","volume":"31","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.074_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomized clinical trial phase I study in Indonesian adults and children: safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.074_b0155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphTM) in Indian children: School based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.09.074_b0160","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1128\/IAI.72.11.6586-6588.2004","article-title":"Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children","volume":"72","author":"Canh","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.09.074_b0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.074_b0170","article-title":"Safety and Immunogenicity of Salmonella Typhi Vi conjugate vaccine (Peda TyphTM) in children upto five years","volume":"3","author":"Chinnasami","year":"2013","journal-title":"Int J Sci Res Publ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19313027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19313027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:56Z","timestamp":1759401836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19313027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":34,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X19313027"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.074","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}